


HIGH-LEVEL INDICATORS


90% reduction in the number of TB deaths by 2030* Estimated data	Baseline 2015 25,100	Milestone 2020 16,300	Target 2030 2,500
--	--------------------------------	---------------------------------	-----------------------------

**Estimated TB Deaths in the Americas:
Trend, Milestones, and Targets**



80% reduction in TB incidence rate by 2030* Estimate x 100,000 pop.	Baseline 2015 27.3	Milestone 2020 21.8	Target 2030 5.5
---	------------------------------	-------------------------------	---------------------------

**Estimated TB incidence in the Americas:
Trend, Milestones, and Targets**



TB-affected households that face catastrophic costs due to TB (%)	Baseline 2015 NA**	Milestone 2020 0%	Target 2030 0%
--	------------------------------	-----------------------------	--------------------------

* Compared to 2015
** Not available

Number of reported TB deaths. 2017 Vital Statistics

Country	Deaths in 2017***
Brazil	6,376
Mexico	2,535
Peru	1,617
Colombia	1,308
Argentina	706
Ecuador	594
United States of America	562
Chile	438
Guatemala	337
Panama	280
Paraguay	218
Nicaragua	153
Canada	106
Uruguay	74
Cuba	48
Costa Rica	43
Puerto Rico	5
Total	15,400

*** Including TB-HIV cases

- 17 countries reported 15,400 TB deaths based on their 2017 vital statistics. Many of these deaths could have been prevented.
- In 2018, the TB case detection gap in the Region was 53,500 cases.
- In the last 5 years, the incidence rate has increased 1.5% per year. To achieve 2020 Milestone of the End TB Strategy targets, there must be a 12% annual decline.
- Countries in the Region must conduct surveys on the catastrophic costs incurred by affected households.

END TB STRATEGY - PRIORITY INDICATORS

INDICATOR		2018 FIGURES	2025 TARGET
TB treatment coverage*		81%	≥ 90%
Treatment success rate	New and Relapsed (2017)	76%	≥ 90%
	RR/MDR (2016)	59%	
Percentage of TB-affected households that face catastrophic costs due to TB		NA**	0%
Percentage of new TB patients diagnosed using WHO-recommended rapid tests		18%	≥ 90%
Latent TB infection treatment coverage	Children under 5	56%	≥ 90%
	HIV	9%	≥ 90%
Contact investigation coverage		NA**	≥ 90%
TB patients with drug-susceptibility testing (DST) results		35%	100%
New TB drug treatment coverage		NA**	≥ 90%
Percentage of TB patients who know their HIV status		82%	100%
TB case fatality rate***		7%***	≤ 5%

* Calculated based on the estimated number of incident cases

** Not available

*** Based on 2017 figures

Recommendations for accelerating progress toward ending TB in the Americas:

1. Improve and/or accelerate the implementation and expansion of early diagnosis with the new rapid molecular tests.
2. Promote the study of contacts, mainly among children under 15.
3. Accelerate implementation of the new MDR-TB regimens and the introduction of dispersible pediatric drugs to improve TB treatment outcomes.
4. Increase work with vulnerable populations and on social determinants through interprogrammatic and intersectoral people- and community-centered activities.
5. Promote special approaches such as the Tuberculosis Control in Large Cities Initiative, the Parliamentary Front against TB, and the expansion of operational research.
6. Cover the existing financial gaps with sustainable resources, reducing dependence on external funding.